JP2006513154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513154A5 JP2006513154A5 JP2004544675A JP2004544675A JP2006513154A5 JP 2006513154 A5 JP2006513154 A5 JP 2006513154A5 JP 2004544675 A JP2004544675 A JP 2004544675A JP 2004544675 A JP2004544675 A JP 2004544675A JP 2006513154 A5 JP2006513154 A5 JP 2006513154A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- cycloalkyl
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 229920001515 polyalkylene glycol Chemical group 0.000 claims description 20
- 125000003827 glycol group Chemical group 0.000 claims description 17
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- -1 cyano, nitro, amino Chemical group 0.000 claims description 7
- 125000005190 thiohydroxy group Chemical group 0.000 claims description 7
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 239000011593 sulfur Substances 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- ZWJINEZUASEZBH-UHFFFAOYSA-N Fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims 10
- PIGFYZPCRLYGLF-UHFFFAOYSA-N aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 239000011574 phosphorus Substances 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000002829 nitrogen Chemical class 0.000 claims 5
- 102000003734 Voltage-gated potassium channels Human genes 0.000 claims 4
- 108090000013 Voltage-gated potassium channels Proteins 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 125000002723 alicyclic group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 150000003017 phosphorus Chemical class 0.000 claims 4
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 4
- 125000005309 thioalkoxy group Chemical group 0.000 claims 4
- 125000005296 thioaryloxy group Chemical group 0.000 claims 4
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 claims 3
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical class C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 claims 3
- 210000003618 cortical neuron Anatomy 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010057666 Anxiety disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010004938 Bipolar disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 206010015037 Epilepsy Diseases 0.000 claims 2
- 208000004559 Hearing Loss Diseases 0.000 claims 2
- 206010011879 Hearing loss Diseases 0.000 claims 2
- 206010061256 Ischaemic stroke Diseases 0.000 claims 2
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 claims 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 2
- 206010027175 Memory impairment Diseases 0.000 claims 2
- 206010027599 Migraine Diseases 0.000 claims 2
- 208000008085 Migraine Disorders Diseases 0.000 claims 2
- 208000005264 Motor Neuron Disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 208000004296 Neuralgia Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims 2
- 201000004569 blindness Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000008895 mood disease Diseases 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N Anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims 1
- 102000015686 KCNQ3 Potassium Channel Human genes 0.000 claims 1
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 claims 1
- 206010024094 Learning disease Diseases 0.000 claims 1
- 206010061284 Mental disease Diseases 0.000 claims 1
- 206010028003 Motor neurone disease Diseases 0.000 claims 1
- 230000000111 anti-oxidant Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000003340 mental Effects 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 229920001281 polyalkylene Polymers 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 10
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41952502P | 2002-10-21 | 2002-10-21 | |
| PCT/IL2003/000855 WO2004035037A2 (fr) | 2002-10-21 | 2003-10-21 | Derives d'acide n-phenylanthranilique et de 2-benzimidazolone en tant que modulateurs de l'activite des canaux potassiques et/ou des neurones corticaux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006513154A JP2006513154A (ja) | 2006-04-20 |
| JP2006513154A5 true JP2006513154A5 (fr) | 2006-12-07 |
Family
ID=32108098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004544675A Pending JP2006513154A (ja) | 2002-10-21 | 2003-10-21 | カリウムチャネルおよび／または皮質ニューロン活性モジュレーターとしての、ｎ−フェニルアントラニル酸および２−ベンズイミダゾロンの誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1553932A2 (fr) |
| JP (1) | JP2006513154A (fr) |
| KR (1) | KR20050074493A (fr) |
| AU (1) | AU2003272068A1 (fr) |
| CA (1) | CA2503075A1 (fr) |
| WO (1) | WO2004035037A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| CN101868443A (zh) | 2007-09-20 | 2010-10-20 | 特拉维夫大学拉莫特有限公司 | N-苯基邻氨基苯甲酸衍生物及其用途 |
| GB0723794D0 (en) | 2007-12-05 | 2008-01-16 | Lectus Therapeutics Ltd | Potassium ion channel modulators and uses thereof |
| GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| US11427531B2 (en) | 2017-10-09 | 2022-08-30 | Ramot At Tel-Aviv University Ltd. | Modulators of potassium ion and TRPV1 channels and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5032189A (fr) * | 1973-07-20 | 1975-03-28 | ||
| JPS5095285A (fr) * | 1973-12-26 | 1975-07-29 | ||
| JPH05132431A (ja) * | 1990-03-28 | 1993-05-28 | Nippon Oil & Fats Co Ltd | 高分子化薬剤およびその製造法 |
| US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| ITMI962356A1 (it) * | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
| EP0993437B1 (fr) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | Derives d'acide benzoique 2-(4-bromo ou 4-iodo phenylamino) et utilisation de ces derniers en tant qu'inhibiteurs de mek |
| US6291442B1 (en) * | 1998-02-03 | 2001-09-18 | The General Hospital Corporation | Pharmacological modulators of voltage-gated potassium ion channels |
| CA2349616A1 (fr) * | 1998-12-04 | 2000-06-15 | Neurosearch A/S | Nouveaux derives de benzimidazolone, de benzoxazolone ou de benzothiazolone agissant comme agents de modulation de canaux ioniques |
| US6472165B1 (en) * | 1999-08-03 | 2002-10-29 | Arzneimittelwerk Dresden Gmbh | Modulatory binding site in potassium channels for screening and finding new active ingredients |
| US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| CA2406383A1 (fr) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | Agents de reduction de a.beta.42 |
| US6429223B1 (en) * | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
| TWI287984B (en) * | 2000-10-17 | 2007-10-11 | Wyeth Corp | Pharmaceutical composition for modulating bladder function |
| GB0026838D0 (en) * | 2000-11-02 | 2000-12-20 | Glaxo Group Ltd | Treatment method |
| US6593349B2 (en) * | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| CN101868443A (zh) * | 2007-09-20 | 2010-10-20 | 特拉维夫大学拉莫特有限公司 | N-苯基邻氨基苯甲酸衍生物及其用途 |
-
2003
- 2003-10-21 KR KR1020057006856A patent/KR20050074493A/ko not_active Application Discontinuation
- 2003-10-21 CA CA002503075A patent/CA2503075A1/fr not_active Abandoned
- 2003-10-21 WO PCT/IL2003/000855 patent/WO2004035037A2/fr active Application Filing
- 2003-10-21 JP JP2004544675A patent/JP2006513154A/ja active Pending
- 2003-10-21 AU AU2003272068A patent/AU2003272068A1/en not_active Abandoned
- 2003-10-21 EP EP03753909A patent/EP1553932A2/fr not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100369894C (zh) | 氧化氮合酶抑制剂磷酸盐 | |
| CN1043531C (zh) | 嘧啶衍生物及其制备方法和用途 | |
| WO2005092895A3 (fr) | Composes acide propanoique beta piperidino methyle alpha aryle ou heteroaryle utilises comme antagonistes du recepteur orl1 | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| JP2005519932A5 (fr) | ||
| RU2004111979A (ru) | Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью | |
| RU2004107131A (ru) | Новые производные 4,5-дигидро-1h-пиразола, имеющие cb1- антагонистическую активность | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2006504710A5 (fr) | ||
| MA32088B1 (fr) | Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique | |
| ATE478872T1 (de) | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung | |
| EP1619192A3 (fr) | Composes azapolycycliques a fusion aryle | |
| RU2006131132A (ru) | 1,3,5,-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью | |
| JP2006502119A5 (fr) | ||
| MX2010006182A (es) | Derivados de isoxazolo-piridazina. | |
| EP2423207A3 (fr) | Derives de pyrimidone substitues en position 2 par une amine cyclique en tant qu'inhibiteurs de TPK1 | |
| AU623733B2 (en) | Benzofused-n-containing heterocyle derivatives | |
| KR960700268A (ko) | 티아졸리딘 유도체, 이의 제조 방법 및 이를 함유한 약제(thiazolidine derivatives, prepartion thereof and drugs containing same) | |
| EP2412707A3 (fr) | Derives d'acide 3-[2-(3-amino-2-oxo-2H-pyridin-1-yl) acetylamino]-4-oxo-pentanoique et leur utilisation comme inhibiteurs de caspase | |
| CA2336412A1 (fr) | Medicament pour le traitement du diabete | |
| JP2019527724A5 (fr) | ||
| EP2088142A3 (fr) | Dihydropyrimidines, leur procédé de préparation et leur utilisation. | |
| JP2006513154A5 (fr) | ||
| PL1911746T3 (pl) | Substancja wykazująca działanie przeciwutleniające, przeciwstarzeniowe i przeciwniedokrwienne oraz sposób jej wytwarzania | |
| CA2440014A1 (fr) | Derives de beta-carboline et leur utilisation pharmaceutique contre la depression et l'anxiete |